Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(3 years from now) | |
US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(3 years from now) | |
US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(15 years from now) | |
US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-270) | Sep 20, 2024 |
New Indication(I-907) | Dec 19, 2025 |
New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture; Use for detecting neutraliz...
Dosage: SOLUTION;SUBCUTANEOUS